The Antimicrobial Peptide Human Beta-Defensin-3 Is Induced by Platelet-Released Growth Factors in Primary Keratinocytes

Andreas Bayer, Justus Lammel, Mersedeh Tohidnezhad, Sebastian Lippross, Peter Behrendt, Tim Klüter, Thomas Pufe, Jochen Cremer, Holger Jahr, Franziska Rademacher, Regine Gläser, and Jürgen Harder

1Department of Heart and Vascular Surgery, University Hospital of Schleswig-Holstein, Campus Kiel, Arnold-Heller Straße 3, Haus 26, 24105 Kiel, Germany
2Department of Dermatology, University Hospital of Schleswig-Holstein, Campus Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany
3Institute of Anatomy and Cell Biology, RWTH University of Aachen, Wendlingweg 2, 52072 Aachen, Germany
4Department of Traumatology, University Hospital of Schleswig-Holstein, Campus Kiel, Arnold-Heller Straße 3, Haus 18, 24105 Kiel, Germany
5Department of Orthopaedics, Aachen University Hospital, Pauwelsstraße 30, 52074 Aachen, Germany

Correspondence should be addressed to Andreas Bayer; andreasbayer-kiel@web.de

Received 19 January 2017; Accepted 6 July 2017; Published 25 July 2017

Academic Editor: Vinod K. Mishra

Copyright © 2017 Andreas Bayer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Platelet-released growth factors (PRGF) and its related clinically used formulations (e.g., Vivostat Platelet-Rich Fibrin (PRF®)) contain a variety of chemokines, cytokines, and growth factors [1–5]. The in vitro capacities of PRGF to stimulate cell proliferation and tissue regeneration, to modify cell and tissue differentiation, and to support angiogenesis [6–12] suggest that PRGF may serve as an optimal therapeutic tool for the treatment of chronic or complicated wounds. Accordingly, its clinically related formulation Vivostat PRF has already been used successfully to support healing of patients’ hard-to-heal wounds in vivo [13]. However, the underlying mechanisms of these observed beneficial in vivo effects are not well understood.

In general, one possible reason for a malfunctioning wound healing process of the skin is a local wound infection with potential pathogenic bacterial species. In this situation, human keratinocytes establish a chemical defense system based on the production of antimicrobial peptides, for example, human beta-defensin- (hBD-) 2 and hBD-3 to defeat these microbial threats [14–16]. Recently, we demonstrated that PRGF induces the antimicrobial peptide hBD-2 in

1. Introduction

Platelet-released growth factors (PRGF) is a thrombocyte concentrate lysate comprising a multitude of chemokines, cytokines, and growth factors [1–5]. The in vitro capacities of PRGF to stimulate cell proliferation and tissue regeneration, to modify cell and tissue differentiation, and to support angiogenesis [6–12] suggest that PRGF may serve as an optimal therapeutic tool for the treatment of chronic or complicated wounds. Accordingly, its clinically related formulation Vivostat PRF has already been used successfully to support healing of patients’ hard-to-heal wounds in vivo [13]. However, the underlying mechanisms of these observed beneficial in vivo effects are not well understood.

In general, one possible reason for a malfunctioning wound healing process of the skin is a local wound infection with potential pathogenic bacterial species. In this situation, human keratinocytes establish a chemical defense system based on the production of antimicrobial peptides, for example, human beta-defensin- (hBD-) 2 and hBD-3 to defeat these microbial threats [14–16]. Recently, we demonstrated that PRGF induces the antimicrobial peptide hBD-2 in
primary keratinocytes [17] showing for the first time that PRGF is able to induce the expression of antimicrobial peptides in cultured keratinocytes as well as in wounded skin.

Human beta-defensin-3 (hBD-3) is another important antimicrobial peptide involved in cutaneous defense and was originally isolated from lesional psoriatic skin [18]. hBD-3 is expressed in many epithelia (e.g., skin, respiratory tract, digestive tract, and genitourinary tract) [14, 15, 19–21]. Its expression was shown to be induced by cytokines or microbial stimuli [16, 22]. Hirsch et al. showed that hBD-3 expression significantly promotes wound closure in S. aureus-infected diabetic wounds in a preclinical large-animal model [23]. Furthermore, a tenfold reduction in bacterial growth on day 4 was detected in this study indicating that human beta-defensin-3 may play a major role at least in diabetic wound healing and wound infections [23]. As these data suggest an important role of hBD-3 for the wound healing process, we analyzed the influence of PRGF on hBD-3 expression in human primary keratinocytes in vitro and of Vivostat PRF on hBD-3 expression in artificially generated human skin wounds in vivo.

2. Materials and Methods

2.1. Preparation of PRGF. PRGF was isolated from platelet lysates of several freshly donated human thrombocyte concentrates received from the Institute of Transfusion Medicine, University of Schleswig-Holstein, Campus Kiel. These thrombocyte concentrates were centrifuged for 10 minutes at 2000g. The thrombocyte pellet was washed twice with sodium citrate buffer (0.11 mM, pH 5.5, 37°C) and centrifuged again for 10 min at 2000g. Afterwards, the thrombocytes were resuspended in half the volume of the initial thrombocyte concentrate volume using Keratinocyte Growth Medium 2 (KGM-2; PromoCell, Heidelberg, Germany) without supplements. The thrombocytes were lysed on ice by ultrasound and stored at −80°C for 24 hours and again lysed by ultrasound and stored at −80°C for 24 hours. Subsequently, cell debris was removed by centrifugation for 1 minute at 18,000g, and the remaining supernatant (now named PRGF) was stored in aliquots at −20°C.

2.2. Culture and Stimulation of Primary Human Keratinocytes. Foreskin-derived primary human keratinocytes pooled from different individuals (PromoCell, Heidelberg, Germany) were cultured in KGM-2 at 37°C in a humidified atmosphere with 5% CO2. Stimulation of the keratinocytes with the indicated concentration of PRGF was done in 12-well tissue culture plates (BD Biosciences, Franklin Lakes, New Jersey) when the cells reached a confluence of 90–100%. We used the EGFR-blocking antibody cetuximab (Merck, Darmstadt, Germany) at a concentration of 20 μg/ml and the IL-6 receptor-blocking antibody tocilizumab (Hoffmann-La Roche, Basel, Switzerland) at a concentration of 50 μg/ml to analyze the influence of the EGFR and the IL-6 receptor on hBD-3 induction. After stimulation, we harvested the supernatants for ELISA and washed the cells with 1 ml per well of PBS before RNA isolation.

2.3. RNA Isolation and cDNA Synthesis. To isolate total RNA, keratinocytes derived from one well of a 12-well plate were lysed with 500 μl Crystal RNAmagic reagent, and total RNA was isolated as recommended in the supplier’s protocol (BiolaProducts, Beebensee, Germany). Determination of RNA quantity and quality was carried out photometrically using a NanoDrop device (Peqlab, Erlangen, Germany). 1 μg total RNA served as a template in a reverse transcription reaction using oligo-dT-primers and 50 units Maxima Reverse Transcriptase (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer’s protocol. The resulting cDNA was stored at −20°C until use.

2.4. Real-Time PCR. For real-time PCR analyses, we used a fluorescence temperature cycler (StepOnePlus, Life Technologies) as previously described [24]. The following intron-spanning primers were used: hBD-3—5′-TGT TCC TGT-3′ (forward primer) and 5′-CGC CTC TGA CTC TGC AAT AA-3′ (reverse primer), and RPL38 (ribosomal protein L38)—5′-TCA AGG ACT TCC TGC TCA C-3′ (forward primer) and 5′-AAA GGT ATC TGC TGC ATC GAA-3′ (reverse primer). Serial dilutions of cDNA served as standards to obtain standard curves for relative quantification. Relative gene expression is depicted as the ratio between hBD-3 expression and expression of the housekeeping gene RPL38.

2.5. Luciferase Reporter Assays. To analyze activation of the hBD-3 promoter activity, a firefly luciferase plasmid containing 2484 bp of the human hBD-3 promoter was used. The hBD-3 promoter region was amplified using the primers 5′-AGC CTC GAG TGC AGT TCC TAC GAC-3′ and 5′-CAG AAG CTT GGA TGA AAA GGT GTG CTG GGT C-3′. Both primers contain recognition sites for the restriction enzymes Xhol and HindIII, respectively, to facilitate subsequent cloning into the promoterless pGL3-basic firefly luciferase vector (Promega, Madison, WI). Verification of the correct insertion of the hBD-3 promoter region into the pGL3-basic plasmid was done by sequencing. To analyze hBD-3 promoter activity, 0.5 μg of the hBD-3 firefly promoter plasmid was transfected together with 0.05 μg of an internal control Renilla luciferase expression plasmid (pGL4.74[hRluc/TK], Promega) in primary keratinocytes (70–90% confluence) using the transfection reagent FuGENE HD (Promega). After 6 hours, the transfection medium was removed and replaced by fresh medium. After additional 20–24 hours, cells were stimulated with PRGF (1 : 10 diluted in KGM-2) for 24 hours. Luciferase activity was analyzed using the Dual-Luciferase Assay System (Promega) on a TD-20/20 luminometer (Turner Design, Sunnyvale, CA). Relative promoter activity was calculated as the ratio between firefly and Renilla luciferase activity.

2.6. Analyses of the Influence of Vivostat PRF on the hBD-3 Expression in Keratinocytes In Vivo. We generated bilateral gluteal wounds in five male healthy volunteers by a punch biopsy (Ø 4 mm) after local anesthesia. Immediately, we treated the wounds with either NaCl 0.9% (left) or freshly produced Vivostat PRF (right). The remaining Vivostat
PRF was stored at −20°C. After 5 days, we thawed the frozen Vivostat PRF and repeated the wound treatment. On day 10, we set local anesthesia, resected the bilateral wound areas by punch biopsies (Ø 6 mm), and bisected the received skin biopsies. One-half of the biopsy was used for RNA isolation using the RNAeasy kit (Qiagen, Hilden, Germany). Reverse transcription of the RNA and real-time PCR were performed as described above. The second half of the biopsy was embedded in paraffin and used for hBD-3 immunohistology as described recently [21]. This study was approved by the university committee for ethical affairs, Kiel (AZ A115/13), in accordance with the Helsinki guidelines. All participants included in this investigation provided written informed consent.

2.7. Statistics. GraphPad Prism 6.07 was used for statistical analysis and was carried out by Student’s t-test. A p value of <0.05 was considered statistically significant.

3. Results

3.1. Stimulation of Human Primary Keratinocytes with PRGF Induces hBD-3 Expression. We stimulated human primary keratinocytes with different concentrations of PRGF for 24 hours to analyze PRGF-mediated induction of hBD-3 gene expression in human primary keratinocytes. PRGF stimulation caused a significant induction of hBD-3 gene expression (Figure 1(a)). In concordance with hBD-3 gene expression, PRGF induced also activation of the hBD-3 promoter as analyzed by an hBD-3 reporter luciferase plasmid (Figure 1(b)).

3.2. The PRGF-Mediated hBD-3 Induction in Primary Human Keratinocytes Is Time-Dependent. We analyzed hBD-3 gene expression after 4, 12, 24, 48, and 72 hours of PRGF stimulation to assess the time kinetic of PRGF-mediated hBD-3 induction. hBD-3 was significantly induced in primary keratinocytes after 24 hours of PRGF stimulation (Figure 2). The high hBD-3 induction persisted after 48–72 hours of treatment periods (Figure 2).

3.3. The PRGF-Induced hBD-3 Expression in Primary Keratinocytes Is Partially Mediated by the Epidermal Growth Factor Receptor (EGFR). We used a specific monoclonal EGFR-blocking antibody (cetuximab) to investigate the possible influence of the EGF receptor on the PRGF-mediated induction of hBD-3 in primary human keratinocytes. Treatment of PRGF-stimulated keratinocytes with cetuximab caused a significant decrease in the PRGF-induced hBD-3 gene expression (Figure 3).

3.4. The Influence of the Interleukin-6 Receptor (IL-6R) on the PRGF-Induced hBD-3 Expression in Human Primary Keratinocytes. Since we have previously shown that PRGF rapidly induced IL-6 gene expression in primary human keratinocytes [17], we investigated the possible role of IL-6 on the PRGF-mediated hBD-3 induction in human keratinocytes by blocking the IL-6 receptor with the IL-6 receptor-neutralizing antibody tocilizumab. Treatment of keratinocytes with tocilizumab partially blocked the PRGF-induced hBD-3 gene expression; however, this was statistically not significant (Figure 4).

3.5. Vivostat PRF Treatment of Cutaneous Wounds Resulted in an Increased Expression of hBD-3 in Human Epidermis In Vivo. To assess whether the in vitro results are transferable into the in vivo situation, we sought to determine the

![Figure 1](image1.png)

**Figure 1:** Expression of hBD-3 is induced in primary human keratinocytes by PRGF treatment. (a) Primary keratinocytes were treated with different PRGF concentrations (PRGF 1:50, 1:20, and 1:10 diluted in cell culture medium) for 24 hours. Subsequently, RNA was isolated and reverse-transcribed in cDNA, and hBD-3 gene expression was analyzed by real-time PCR. (b) hBD-3 promoter activation was analyzed in keratinocytes transfected with a hBD-3 promoter luciferase plasmid after stimulation with PRGF (diluted to 1:10 in cell culture medium) for 24 hours (⁎⁎p < 0.01, ⁎⁎⁎p < 0.001, ns = not significant, Student’s t-test).
influence of Vivostat PRF on the hBD-3 expression in experimentally generated gluteal skin wounds of five male healthy volunteers. These wounds were generated bilaterally by 4 mm punch biopsies. On day zero and day five, left wounds were treated with NaCl 0.9% as a control whereas right wounds were treated with Vivostat PRF. On day ten, bilateral wound areas were resected by 6 mm biopsy punches, bisected, and used either for RNA isolation, cDNA synthesis, and real-time PCR analysis or for immunohistological analyses of hBD-3 expression. This in vivo study revealed a significant induction of hBD-3 gene expression in Vivostat PRF-treated wounds (Figure 5(a)) which was accompanied by an increased hBD-3 staining in the Vivostat PRF-treated wounds compared to the control wounds (Figure 5(b)).

4. Discussion

In western countries, about 3% of the population suffer from chronic leg ulcers causing an immense personal, financial (approximately 2.5% of total healthcare budgets in Europe and America), and social burden [25]. Therapeutic options for the therapy of chronic, hard-to-heal wounds are rare, expensive, and often insufficient. Frequently, worsening hard-to-heal wounds result in patients’ minor or even major extremity amputation.

Thrombocyte concentrate lysates generally contain a variety of chemokines, cytokines, and growth factors [1–5] which are able to stimulate cell proliferation and tissue regeneration, to modify cell and tissue differentiation, and to support angiogenesis. This qualifies thrombocyte concentrate lysates as a potential therapeutic tool for the treatment of hard-to-heal wounds in vivo. Indeed, the regenerative, reparative, and angiogenetic potential of thrombocyte concentrate lysates leads to an increased use in many medical disciplines [26–30]. Surprisingly, only a few studies about treatment of
patients’ chronic skin ulcers with thrombocyte concentrate lysates (e.g., Vivostat PRF) are published. In a small study of chronic skin ulcers, superior healing rates by local treatment with a platelet concentrate lysate compared with a standard control treatment were revealed [31]. Local PRGF treatment was also reported to heal a chronic severe mal perforant foot ulcer in a diabetic patient [32]. Steenvoorde et al. described the use of Vivostat PRF on a variety of hard-to-heal wounds which caused complete wound healing or a significant reduction in wound diameter in a majority of treated patients [13]. Using Vivostat PRF for the local treatment of chronic or complicated wounds, we observed in our own department a complete wound healing in 32% and a reduction in the wound diameter in 26% of these patients (n = 50).

Despite these positive clinical experiences with thrombocyte concentrate lysates for the therapy of chronic skin ulcers, only little is known about possible involved mechanisms [8, 11, 12, 33–35]. As we have recently shown that platelet-released growth factors induce the antimicrobial peptide human beta-defensin-2 in primary keratinocytes [17], we now aimed to analyze the influence of PRGF on the expression of hBD-3 in keratinocytes, because hBD-3 belongs to the innate epithelial defense system and seems to play an important role in the wound healing process [22, 23]. Human beta-defensin-3 (hBD-3) was originally isolated from lesional psoriatic skin extracts [18] and is inducibly expressed in many epithelia as the skin and respiratory, digestive, and genitourinary tract [16, 19, 21, 36, 37]. In contrast to hBD-2, hBD-3 is a multifunctional peptide. Compared to hBD-2, hBD-3 offers broader antimicrobial effects [15, 19, 20, 38, 39] even against multiresistant bacterial strains [40], fungi, and viruses [41, 42]. Its functional relevance was demonstrated by Kisich et al. who showed that the constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on hBD-3 [38]. Besides its antimicrobial and wound closure properties, hBD-3 activates different immune and inflammatory cells and stimulates epidermal keratinocyte migration and proliferation and production of proinflammatory cytokines and chemokines [43]. Therefore, hBD-3 displays a key mediator in skin immunity and wound healing.

In our study, we noticed a significant concentration-dependent induction of hBD-3 gene expression in PRGF-treated keratinocytes. Moreover, hBD-3 gene induction in keratinocytes by PRGF treatment was time-dependent with the highest levels after 24–72 hours.
These in vitro data were consistent with our in vivo experiments where we depicted that treatment of cutaneous wounds with Vivostat PRF caused a strong induction of hBD-3 in the keratinocytes in vivo. In summary, the results of our experiments identify PRGF in vitro and Vivostat PRF in vivo as a potent activator of epidermal hBD-3 expression.

It is known that hBD-3 can be induced via activation of the epidermal growth factor receptor (EGFR) [39, 44]. Therefore, we hypothesized that PRGF induces hBD-3 via activation of the EGFR pathway similarly as recently reported for hBD-2 [17]. To prove this hypothesis, we used an antibody (cetuximab) directed against the EGFR. Blocking the EGFR significantly inhibited the induction of hBD-3 in keratinocytes by PRGF indicating an essential role of the EGFR in the PRGF-mediated hBD-3 induction. This is in concordance with a study demonstrating that stimulation of keratinocytes with EGFR ligands strongly induced hBD-3 expression [45]. It remains to be shown whether the observed PRGF-induced hBD-3 induction may be directly mediated by EGFR ligands present in the PRGF.

Another study reported that expression of hBD-3 in keratinocytes is induced upon wounding in an EGFR-dependent manner [46]. The critical role of hBD-3 in wound healing is further documented by studies reporting on the capacity of hBD-3 to promote wound healing [23] and to control the growth of wound-related pathogens including multiresistant strains [38, 40]. Since bacterial biofilms exhibit a negative effect on wound healing, it is of special interest that hBD-3 is able to reduce bacterial biofilm development [47, 48]. These observations suggest that hBD-3 induction by PRGF may contribute to the observed positive clinical effect of thrombocyte concentrate lysates on human wound healing. Its capability to induce antimicrobial peptides such as hBD-3 and hBD-2 [17] may also endow thrombocyte concentrate lysate with the potential to protect from wound infections.

Interleukin-6 (IL-6) is a multifunctional cytokine produced by various cell types that also influences various cell types and has multiple biological activities [49]. It regulates immune responses, hematopoiesis, acute-phase responses, and inflammation and plays a critical role in the pathogenesis of various immune processes and epithelial immune responses [50–54]. Since we recently demonstrated that PRGF induced the expression of IL-6 in human primary keratinocytes [17], we sought to evaluate if the observed PRGF-mediated hBD-3 induction is IL-6-dependent. Therefore, we used an antibody (tocilizumab) directed against the IL-6 receptor to inhibit the IL-6 signaling pathway. Blocking the IL-6 receptor resulted in a reduced hBD-3 gene induction, but this reduction achieved no statistical significance. Thus, in contrast to hBD-2 [17], IL-6 signaling seems to play only a marginal—if any—role for the observed PRGF-induced hBD-3 expression. This is in concordance with that of studies demonstrating that IL-6 has no major influence on hBD-3 expression in keratinocytes [55] and underlines the biological differences between hBD-2 and hBD-3.

5. Conclusion

We identified PRGF in vitro as a potent inducer of hBD-3 in primary keratinocytes. The induced hBD-3 expression was concentration- and time-dependent and partially mediated by the EGFR. In line with these in vitro data, our human in vivo study revealed an upregulation of hBD-3 expression in experimentally generated wounds upon treatment with Vivostat PRF. The PRGF- and Vivostat PRF-induced hBD-3 expression in primary human keratinocytes could be one of the mechanisms leading to the improved clinical outcome often seen after treatment of chronic and/or infected wounds with Vivostat PRF.

Conflicts of Interest

The authors have no financial and personal relationship related to this study (including the relationship to Vivostat).

Authors’ Contributions

Andreas Bayer, Justus Lammel, Mersedeh Tohidnezhad, and Jürgen Harder contributed equally to this work.

Acknowledgments

The authors thank Heilwig Hinrichs and Cornelia Wilgus for the excellent technical support. Materials for the preparation of Vivostat PRF in the in vivo experiments were kindly provided by Vivostat A/S (Alleroed, Denmark).

References

[1] B. L. Eppley, J. E. Woodell, and J. Higgins, “Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing,” Plastic and Reconstructive Surgery, vol. 114, no. 6, pp. 1502–1508, 2004.
[2] G. Weibrich, R. S. R. Buch, W. K. G. Kleis, G. Hafner, W. E. Hitzler, and W. Wagner, “Quantification of thrombocyte growth factors in platelet concentrates produced by discontinuous cell separation,” Growth Factors (Chur, Switzerland), vol. 20, no. 2, pp. 93–97, 2002.
[3] M. Yazawa, H. Ogata, T. Nakajima, T. Mori, N. Watanabe, and M. Handa, “Basic studies on the clinical applications of platelet-rich plasma,” Cell Transplantation, vol. 12, no. 5, pp. 509–518, 2003.
[4] E. Anitua, I. Andia, B. Ardanza, P. Norden, and A. T. Norden, “Autologous platelets as a source of proteins for healing and tissue regeneration,” Thrombosis and Haemostasis, vol. 91, no. 1, pp. 4–15, 2004.
[5] J. van den Dolder, R. Moorer, A. P. G. Vloon, P. J. W. Stoeelinga, and J. A. Jansen, “Platelet-rich plasma: quantification of growth factor levels and the effect on growth and differentiation of rat bone marrow cells,” Tissue Engineering, vol. 12, no. 11, pp. 3067–3073, 2006.
[6] R. Yamaguchi, H. Terasima, S. Yoneyama, S. Tanago, and N. Ohkohchi, “Effects of platelet-rich plasma on intestinal anastomotic healing in rats: PRP concentration is a key factor,” The Journal of Surgical Research, vol. 173, no. 2, pp. 258–266, 2012.
[7] F. Giajani, S. Ivanovski, S. Ce, F. Ducci, M. Tonetti, and M. Gabriele, “The in vitro effect of different PRP concentrations
on osteoblasts and fibroblasts,” *Clinical Oral Implants Research*, vol. 17, no. 2, pp. 212–219, 2006.

[8] A. Rughetti, I. Giusti, S. D’Ascenzo et al., “Platelet gel-released supernatant modulates the angiogenic capability of human endothelial cells,” *Blood Transfusion*, vol. 6, no. 1, pp. 12–17, 2008.

[9] M. Kakudo, H. Kitoh, K. A. Siwicka, and N. Ishiguro, “The effect of the platelet concentration in platelet-rich plasma gel on the regeneration of bone,” *The Journal of Bone and Joint Surgery*, vol. 90, no. 7, pp. 966–972, 2008.

[10] P. Arpornmaeklong, M. Kochel, R. Depprich, N. R. Kübler, and K. K. Würzler, “Influence of platelet-rich plasma (PRP) on osteogenic differentiation of rat bone marrow stromal cells. An in vitro study,” *International Journal of Oral and Maxillofacial Surgery*, vol. 33, no. 1, pp. 60–70, 2004.

[11] N. Kakudo, N. Morimoto, S. Kushida, T. Ogawa, and K. Kusumoto, “Platelet-rich plasma releasate promotes angiogenesis in vitro and in vivo,” *Medical Molecular Morphology*, vol. 47, no. 2, pp. 83–89, 2014.

[12] N. Kakudo, S. Kushida, T. Minakata, K. Suzuki, and K. Kusumoto, “Platelet-rich plasma promotes epithelialization and angiogenesis in a splitthickness skin graft donor site,” *Medical Molecular Morphology*, vol. 44, no. 4, pp. 233–236, 2011.

[13] P. Steenwoorde, L. P. van Doorn, C. Naves, and J. Oskam, “Use of autologous platelet-rich fibrin on hard-to-heal wounds,” *Journal of Wound Care*, vol. 17, no. 2, pp. 60–63, 2008.

[14] S. Scharf, J. Zahltlen, K. Szynanski, S. Hippenstein, N. Suttorp, and P. D. N’Guessan, “Streptococcus pneumoniae induces human β-defensin-2 and -3 in human lung epithelium,” *Experimental Lung Research*, vol. 38, no. 2, pp. 100–110, 2012.

[15] K. Kawauchi, A. Yagihashi, N. Tsuji et al., “Human beta-defensin-3 induction in H. pylori-infected gastric mucosal tissues,” *World Journal of Gastroenterology*, vol. 12, no. 36, pp. 5793–5797, 2006.

[16] K. Kiehne, A. Fincke, G. Brunke, T. Lange, U. R. Fölsch, and K. H. Herzig, “Antimicrobial peptides in chronic anal fistula epithelium,” *Scandinavian Journal of Gastroenterology*, vol. 42, no. 9, pp. 1063–109, 2007.

[17] A. Bayer, J. Lammel, F. Rademacher et al., “Platelet-released growth factors induce the antimicrobial peptide human beta-defensin-2 in primary keratinocytes,” *Experimental Dermatology*, vol. 25, no. 6, pp. 460–465, 2016.

[18] J. Harder, J. Bartels, E. Christophers, and J. M. Schroder, “Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic,” *The Journal of Biological Chemistry*, vol. 276, no. 8, pp. 5707–5713, 2001.

[19] H. Ishimoto, H. Mucke, Y. Date et al., “Identification of hBD-3 in respiratory tract and serum: the increase in pneumonia,” *The European Respiratory Journal*, vol. 27, no. 2, pp. 253–260, 2006.

[20] P. Zanger, D. Nurjadi, B. Vath, and P. G. Kremser, “Persistent nasal carriage of Staphylococcus aureus is associated with deficient induction of human beta-defensin 3 after sterile wound- ing of healthy skin in vivo,” *Infection and Immunity*, vol. 79, no. 7, pp. 2658–2662, 2011.

[21] M. Wittersheim, J. Cordes, U. Meyer-Hoffert, J. Harder, J. Hedderich, and R. Gläser, “Differential expression and in vivo secretion of the antimicrobial peptides psoriasin (S100A7), RNase 7, human beta-defensin-2 and -3 in healthy human skin,” *Experimental Dermatology*, vol. 22, no. 5, pp. 364–366, 2013.

[22] O. E. Serensen, J. B. Cowland, K. Theiligard-Mönch, L. Liu, T. Ganz, and N. Borregaard, “Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors,” *Journal of Immunology*, vol. 170, no. 11, pp. 5583–5589, 2003.

[23] T. Hirsch, M. Spielmann, B. Zuhaili et al., “Human beta-defensin-3 promotes wound healing in infected diabetic wounds,” *The Journal of Gene Medicine*, vol. 11, no. 3, pp. 220–228, 2009.

[24] S. A. Roth, M. Simanski, F. Rademacher, L. Schröder, and J. Harder, “The pattern recognition receptor NOD2 mediates Staphylococcus aureus-induced IL-17C expression in keratinocytes,” *The Journal of Investigative Dermatology*, vol. 134, no. 2, pp. 374–380, 2014.

[25] C. N. Parker, K. J. Finlayson, P. Shuter, and H. E. Edwards, “Risk factors for delayed healing in venous leg ulcers: a review of the literature,” *International Journal of Clinical Practice*, vol. 69, no. 9, pp. 1029–1030, 2015.

[26] J. Alsoussou, A. Ali, K. Willett, and P. Harrison, “The role of platelet-rich plasma in tissue regeneration,” *Platelets*, vol. 24, no. 3, pp. 173–182, 2013.

[27] J. Alsoussou, M. Thompson, P. Hulley, A. Noble, and K. Willett, “The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature,” *The Journal of Bone and Joint Surgery*, British Volume, vol. 91, no. 8, pp. 987–996, 2009.

[28] L. H. Redler, S. A. Thompson, S. H. Hsu, C. S. Ahmad, and W. N. Levine, “Platelet-rich plasma therapy: a systematic literature review and evidence for clinical use,” *The Physician and Sportsmedicine*, vol. 39, no. 1, pp. 42–51, 2011.

[29] T. E. Foster, B. L. Puskas, B. R. Mandelbaum, M. B. Gerhardt, and S. A. Rodeo, “Platelet-rich plasma: from basic science to clinical applications,” *The American Journal of Sports Medicine*, vol. 37, no. 11, pp. 2259–2272, 2009.

[30] W. Baeyens, R. Glineur, and L. Evrard, “The use of platelet concentrates: platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in bone reconstruction prior to dental implant surgery,” *Revue Médicale de Bruxelles*, vol. 31, no. 6, pp. 521–527, 2010.

[31] E. Aitina, J. J. Aguirre, J. Algorta et al., “Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers,” *Journal of Biomedical Materials Research. Part B, Applied Biomaterials*, vol. 84, no. 2, pp. 415–421, 2008.

[32] B. Orcajo, F. Muruzabal, M. C. Isasmendi et al., “The use of plasma rich in growth factors (PRGF-Endoret) in the treatment of a severe mal perforant ulcer in the foot of a person with diabetes,” *Diabetes Research and Clinical Practice*, vol. 93, no. 2, pp. e65–e67, 2011.

[33] F. Molina-Miñano, P. López-Jornet, F. Camacho-Alonso, and V. Vicente-Ortega, “The use of plasma rich in growth factors on wound healing in the skin: experimental study in rabbits,” *International Wound Journal*, vol. 6, no. 2, pp. 145–148, 2009.

[34] L. J. Xian, S. R. Chowdhury, A. Bin Saim, and R. B. Idrus, “Concentration-dependent effect of platelet-rich plasma on keratinocyte and fibroblast wound healing,” *Cytotherapy*, vol. 17, no. 3, pp. 293–300, 2014.

[35] M. C. Barsotti, M. Chiara Barsotti, P. Losi et al., “Effect of platelet lysate on human cells involved in different phases of wound healing,” *PLoS One*, vol. 8, no. 12, article e84753, 2013.
[36] A. Dunsche, Y. Açıl, H. Domnisch, R. Siebert, J. M. Schröder, and S. Jepsen, “The novel human beta-defensin-3 is widely expressed in oral tissues,” European Journal of Oral Sciences, vol. 110, no. 2, pp. 121–124, 2002.

[37] N. A. Nakra, R. P. Madan, N. Buckley et al., “Loss of innate host defense following unprotected vaginal sex,” The Journal of Infectious Diseases, vol. 213, no. 5, pp. 840–847, 2016.

[38] K. O. Kisch, M. D. Howell, M. Boguniewicz, H. R. Heizer, N. U. Watson, and D. Y. M. Leung, “The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3,” The Journal of Investigative Dermatology, vol. 127, no. 10, pp. 2368–2380, 2007.

[39] Y. H. Firat, M. Simanski, F. Rademacher, L. Schröder, J. Brasch, and J. Harder, “Infection of keratinocytes with Trichophyton rubrum induces epidermal growth factor-dependent RNAse 7 and human beta-defensin-3 expression,” PLoS One, vol. 9, no. 4, article e93941, 2014.

[40] G. Maisetta, G. Batoni, S. Esin et al., “In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 2, pp. 806–809, 2006.

[41] J. R. García, F. Jaumann, S. Schulz et al., “Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macropage chemotaxis,” Cell and Tissue Research, vol. 306, no. 2, pp. 257–264, 2001.

[42] G. Batoni, G. Maisetta, S. Esin, and M. Campa, “Human beta-defensin-3: a promising antimicrobial peptide,” Mini Reviews in Medicinal Chemistry, vol. 6, no. 10, pp. 1063–1073, 2006.

[43] F. Niyonsaba, H. Ushio, N. Nakano et al., “Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines,” The Journal of Investigative Dermatology, vol. 127, no. 3, pp. 594–604, 2007.

[44] J. S. Muhammad, S. F. Zaidi, Y. Zhou, H. Sakurai, and T. Sugiyama, “Novel epidermal growth factor receptor pathway mediates release of human β-defensin 3 from helicobacter pylori-infected gastric epithelial cells,” Pathogens and Disease, vol. 74, no. 3, 2016.

[45] O. E. Sørensen, D. R. Thapa, A. Rosenthal, L. Liu, A. A. Roberts, and T. Ganz, “Differential regulation of beta-defensin expression in human skin by microbial stimuli,” Journal of Immunology, vol. 174, no. 8, pp. 4870–4879, 2005.

[46] O. E. Sørensen, D. R. Thapa, K. M. Roupé et al., “Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1878–1885, 2006.

[47] C. Zhu, H. Tan, T. Cheng et al., “Human β-defensin 3 inhibits antibiotic-resistant Staphylococcus biofilm formation,” Journal of Surgical Research, vol. 183, no. 1, pp. 204–213, 2013.

[48] Q. Huang, H.-J. Yu, G.-D. Liu et al., “Comparison of the effects of human beta-defensin 3, vancomycin, and clindamycin on Staphylococcus aureus biofilm formation,” Orthopedics, vol. 35, no. 1, pp. e53–e60, 2012.

[49] M. Mihsara, M. Hashizume, H. Yoshida, M. Suzuki, and M. Shina, “IL-6/IL-6 receptor system and its role in physiological and pathological conditions,” Clinical Science (London), vol. 122, no. 4, pp. 143–159, 2012.

[50] C. E. Rolle, J. Chen, I. Pastar et al., “Keratinocytes produce IL-6 in response to desmoglein 1 cleavage by Staphylococcus aureus exfoliative toxin A,” Immunologic Research, vol. 57, no. 1–3, pp. 258–267, 2013.

[51] T. Liu, F. Yang, Z. Li, C. Yi, and X. Bai, “A prospective pilot study to evaluate wound outcomes and levels of serum C-reactive protein and interleukin-6 in the wound fluid of patients with trauma-related chronic wounds,” Ostomy/ Wound Management, vol. 60, no. 6, pp. 30–37, 2014.

[52] K. A. Kuhn, N. A. Manieri, T. C. Liu, and T. S. Stappenbeck, “IL-6 stimulates intestinal epithelial proliferation and repair after injury,” PloS One, vol. 9, no. 12, article e114195, 2014.

[53] J. H. Choi, J. H. Jun, J. H. Kim, H. J. Sung, and J. H. Lee, “Synergistic effect of interleukin-6 and hyaluronic acid on cell migration and ERK activation in human keratinocytes,” Journal of Korean Medical Science, vol. 29, Supplement 3, pp. S210–S216, 2014.

[54] I. Arranz-Valsero, L. Soriano-Romani, L. García-Possadas, A. López-García, and Y. Diebold, “IL-6 as a corneal wound healing mediator in an in vitro scratch assay,” Experimental eye Research, vol. 125, pp. 183–192, 2014.

[55] O. E. Sørensen, J. B. Cowland, K. Thielgaard-Mönch, L. Liu, T. Ganz, and N. Borregaard, “Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors,” Journal of Immunology (Baltimore, Md. : 1950), vol. 170, no. 11, pp. 5583–5589, 2003.
Submit your manuscripts at https://www.hindawi.com